CVRx, Inc. (CVRX)

NASDAQ: CVRX · IEX Real-Time Price · USD
9.08 -0.39 (-4.12%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap184.79M
Revenue (ttm)11.47M
Net Income (ttm)-35.91M
Shares Out20.35M
EPS (ttm)-6.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume49,147
Open9.29
Previous Close9.47
Day's Range8.81 - 9.79
52-Week Range8.81 - 29.00
Betan/a
AnalystsBuy
Price Target22.33 (+145.9%)
Earnings DateNov 4, 2021

About CVRX

CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, M...

IndustryMedical Devices
IPO DateJun 30, 2021
Employees63
Stock ExchangeNASDAQ
Ticker SymbolCVRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CVRx, Inc. stock is "Buy." The 12-month stock price forecast is 22.33, which is an increase of 145.93% from the latest price.

Price Target
$22.33
(145.93% upside)
Analyst Consensus: Buy

News

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

1 week ago - GlobeNewsWire

CVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

4 weeks ago - GlobeNewsWire

CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

2 months ago - GlobeNewsWire

CVRx Added to Russell 2000® and 3000® Indexes

MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and mini...

4 months ago - GlobeNewsWire

CVRx Reports Second Quarter 2021 Financial and Operating Results

Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year

5 months ago - GlobeNewsWire

CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

5 months ago - GlobeNewsWire

CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive ...

5 months ago - GlobeNewsWire

CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors

MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive...

6 months ago - GlobeNewsWire

Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx® (NSDQ: CVRX)

SANTA CLARA, Calif. and DUBLIN, July 6, 2021 /PRNewswire/ -- Treo Ventures portfolio company CVRx, Inc. announced the upsized pricing of its initial public offering on the Nasdaq Global Select Market.

6 months ago - PRNewsWire

CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Add...

MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

6 months ago - GlobeNewsWire